5 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18282696 | ENGINEERED IMMUNE CELLS AND USES THEREOF | PUTTLITZ, KARL J | 1646 | Non-Final OA | Sep 18, 2023 |
| 18276703 | ENGINEERED IMMUNE EFFECTOR CELLS EXPRESSING EXOGENOUSLY INTRODUCED CYTOKINES | SHUPE, ELIZABETH A | 1643 | Non-Final OA | Aug 10, 2023 |
| 18039420 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | MELCHIOR, JAMES RYLAND | 1644 | Non-Final OA | May 30, 2023 |
| 18026297 | T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF | BUTTICE, AUDREY L | 1647 | Final Rejection | Mar 14, 2023 |
| 17916370 | COMPOSITIONS AND METHODS FOR REDUCING GRAFT REJECTION IN ALLOGENEIC CELL THERAPY | WILSON, MICHAEL C | 1638 | Non-Final OA | Sep 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial